Biogen reported $100K in Ordinary Share Capital for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ordinary Share Capital Change
Acadia Pharmaceuticals ACAD:US USD 16K 0
Bayer BAYN:GR EUR 2.52B 0
Biogen BIIB:US USD 100K 0
Biomarin Pharmaceutical BMRN:US USD 186K 0
Bluebird Bio BLUE:US USD 829K 94K
Esperion Therapeutics ESPR:US USD 75K 3K
Intercept Pharmaceuticals ICPT:US USD 42K 1000
Intra Cellular Therapies ITCI:US USD 9K 0
Marinus Pharmaceuticals MRNS:US USD 50K 13K
Moderna Inc MRNA:US USD 38.5K 200
Neurocrine Biosciences NBIX:US USD 100K 0
Novartis NOVN:VX USD 890M 0
Ptc Therapeutics PTCT:US USD 72K 1000
Puma Biotechnology PBYI:US USD 5K 0
Sangamo Biosciences SGMO:US USD 1.67M 49K
Sarepta Therapeutics SRPT:US USD 9K 0
Seattle Genetics SGEN:US USD 187K 2K
Teva Pharmaceutical TEVA:IT USD 57M 0
Ultragenyx Pharmaceutical RARE:US USD 70K 0
United Therapeutics UTHR:US USD 700K 0